Vunakizumab treatment for rheumatic autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study is a registry that collects information from people with various rheumatic autoimmune diseases who are using vunakizumab. The goal is to better understand how the medication works in real life, including side effects and how people are doing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a rheumatic autoimmune condition, such as ankylosing spondylitis, psoriatic arthritis, or polymyalgia rheumatica.
- You are currently taking or planning to take the medication vunakizumab (also called fulvezinib).
- You can follow up with your doctor as recommended.
- You are able to understand and sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two new medications, vunakizumab and ivarmacitinib, to see if they are safe and effective at controlling active Takayasu's arteritis. These medicines work differently from your current treatment, so they might help reduce inflammation and prevent more damage to your blood vessels.
This trial tests a new medication called vilamakitug to see if it can reduce pain and inflammation in people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It may help those who haven't found relief with other treatments.
This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This trial tests an oral medication called deucravacitinib (which is already used for psoriasis) to see if it can calm inflammation in Takayasu's arteritis. If you have active disease despite current treatment, this may offer a new option to help control symptoms and prevent damage.
This study tests a new biologic drug called Vunakizumab for people with spondyloarthritis, a type of arthritis that affects the spine and joints. It aims to see if it can reduce inflammation and improve symptoms.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.